Table 6.

Effect of Hormone Therapy on Adjusted CHD Risk by Change in Biomarkers

	First Tertile of Change				Second Tertile of Change				Third Tertile of Change
	Change Value	OR (95% CI)			Change Value	OR (95% CI)			Change Value	OR (95% CI)			P-value for interaction1
Inflammation
C-reactive protein (ug/ml)	< −0.1	0.75	(0.39	1.45)	−0.1 - < 1.7	1.40	(0.72	2.69)	≥1.7	1.39	(0.66	2.93)	0.33
E-selectin (ng/ml)	<−8	1.24	(0.57	2.72)	−8 - < −1	1.38	(0.70	2.70)	≥−1	0.77	(0.40	1.47)	0.08
MMP-9 (ng/ml)	<−25	0.90	(0.49	1.64)	−25 - < 63	0.98	(0.50	1.90)	≥63	1.33	(0.71	2.49)	0.16
Lipids
HDL-cholesterol (mg/dl)	<0	1.06	(0.53	2.11)	0 - < 6	1.34	(0.72	2.49)	≥6	1.29	(0.60	2.78)	0.44
LDL-cholesterol (mg/dl)	<−24	0.69	(0.33	1.43)	−24 - < −2	1.13	(0.55	2.31)	≥ −2	1.37	(0.70	2.70)	0.46
Total cholesterol (mg/dl)	<−21	0.96	(0.50	1.84)	−21 - < 3	0.84	(0.43	1.62)	≥ 3	1.61	(0.84	3.10)	0.19
Triglycerides (mg/dl)	<−7	0.79	(0.42	1.50)	−7 - < 25	2.31	(1.16	4.59)	≥ 25	0.70	(0.38	1.32)	0.65
Thrombosis and other blood markers
Fibrinogen (mg/dl)	<−39	1.13	(0.59	2.17)	−39 - < 12	1.01	(0.55	1.85)	≥ 12	1.27	(0.69	2.33)	0.57
PAI-1 antigen (ng/ml)	<−12.2	1.24	(0.63	2.45)	−12.2 - < 4.2	0.75	(0.37	1.52)	≥ 4.2	0.90	(0.48	1.68)	0.24
PAP (nmol/L)	<−0.1	0.72	(0.37	1.39)	−0.1 - < 1	1.29	(0.64	2.61)	≥ 1	0.89	(0.45	1.75)	0.90
Homocysteine (umol/L)	<−1.1	1.29	(0.70	2.40)	−1.1 - < 0.4	1.31	(0.69	2.49)	≥ 0.4	0.84	(0.45	1.55)	0.29
Glucose (mg/dl)	<−6	0.85	(0.44	1.66)	−6 - < 3	1.10	(0.57	2.12)	≥ 3	1.38	(0.78	2.43)	0.32
Insulin (UIU/ml)	<−1.6	0.89	(0.46	1.70)	−1.6 - < 0.9	1.25	(0.63	2.49)	≥ 0.9	1.09	(0.57	2.07)	0.53

Only biomarkers with significant change in Table 5 are shown.

¹P-value for interaction of active treatment/placebo * biomarker change is based on a 1 degree-of-freedom test for change in biomarker controlling for the same variables as in Table 3.